Podcasts about Cart

Convidada: Marina Pera, analista sênior de risco político da consultoria Control Risks no México. O chefão do cartel Jalisco Nova Geração, um dos mais violentos e poderosos grupos criminosos organizados do México, foi morto no último domingo (22). O megatraficante Nemesio Oseguera Cervantes, conhecido como "El Mencho", foi baleado em uma operação das forças de segurança mexicanas: os agentes monitoraram os passos de sua namorada até uma cabana em Tapalpa, na região montanhosa do estado de Jalisco, onde se deu o confronto. A morte de El Mencho foi o gatilho para uma reação violenta do grupo organizado. Ataques foram registrados em 20 estados mexicanos: criminosos incendiaram veículos, bloquearam rodovias, fecharam escolas e espalharam pânico. O número de mortos já passa de 70, entre policiais, agentes penitenciários e integrantes do cartel. O governo mobilizou mais de 10 mil militares para conter a violência. A morte do chefe do Jalisco Nova Geração abre uma nova fase de incertezas no México, afirma Marina Pera, analista sênior de risco político da consultoria Control Risks no México. Em entrevista a Natuza Nery, ela descreve como El Mencho mantinha seu poder e cultivava uma imagem messiânica diante de seu grupo. Marina também explica por que a queda de uma liderança desse tamanho pode desencadear uma avalanche na estrutura do narcotráfico e nas instituições oficiais mexicanas.

Guest: Dr. Ido Amit is a Principal Investigator and the Eden and Steven Romick Professorial Chair at the Weizmann Institute of Science. His lab is at the forefront of developing and applying cutting-edge single-cell genomics technologies alongside advanced computational approaches. By integrating these innovative tools in both animal models and human studies, his team uncovers the immune regulatory mechanisms and pathways that shape health and disease. Featured Products and Resources: Stay up-to-date with the latest in human immunology news. Download a free wallchart on the production of CAR T cells. The Immunology Science Round Up Modified RNA Prevents Autoimmunity – Researchers show that modified RNA from our own cells naturally blocks TLR7 and TLR8, preventing harmful immune activation. Oncolytic Virus Boosts T Cells – In glioblastoma patients, a single virus treatment helped the immune system attack the tumor. Rewiring the Immune System During Food Scarcity – When food is scarce, stress hormones rebalance the immune system to fight infection while conserving glucose and preserving immune memory. Regulating Bystander T Cells – IL-4 can dial down how strongly memory CD8+ T cells respond to infection without direct antigen stimulation. Image courtesy of Dr. Ido Amit Subscribe to our newsletter! Never miss updates about new episodes. Subscribe

Immune discusses how tattoo ink accumulates in lymph nodes, promotes inflammation and influences response to two different vaccines. Hosts: Vincent Racaniello, Cindy Leifer, Stephanie Langel, and Brianne Barker Subscribe (free): Apple Podcasts, RSS, email Become a patron of Immune! Links for this episode MicrobeTV Discord Server IL-9, CAR T cells and anti-tumor CD8 cells Tattoo ink, inflammation and vaccines Time stamps by Jolene Ramsey. Thanks! Music by Tatami. Immune logo image by Blausen Medical Send your immunology questions and comments to immune@microbe.tv Information on this podcast should not be construed as medical advice.  

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world.Today, we delve into the latest from an industry that continues to break new ground in both scientific innovation and regulatory landscapes. The pharmaceutical and biotech sectors are buzzing with activity as companies engage in bold strategies and face significant challenges in their quest for groundbreaking treatments.A recent event illustrating the high-stakes nature of this industry involves Novo Nordisk and its decision to conduct a head-to-head clinical trial for Cagrisema against Eli Lilly's Zepbound. This trial, which typically occurs post-approval, was conducted at the candidate stage. Novo Nordisk aimed to establish market dominance by proving superiority early on. However, the trial did not go as planned, with Cagrisema failing to outperform Zepbound. This outcome serves as a reminder of the competitive dynamics in early-stage testing and the strategic risks companies are willing to take in their bid for market leadership.Meanwhile, Gilead Sciences has made a bold move with a $7.8 billion investment in Arcellx, focusing on CAR T-cell therapy. This investment highlights Gilead's commitment to advanced cancer treatments, particularly Anito-cel for relapsed or refractory multiple myeloma. CAR T-cell therapies involve modifying a patient's T-cells to target cancer cells more effectively, representing a significant leap forward in oncological treatments. With an FDA decision anticipated by December 2026, Gilead's investment underscores its strategic focus on transformative therapies that could redefine cancer care.In legal news, Regenxbio has secured a notable victory against Sarepta Therapeutics regarding adeno-associated virus (AAV) technology patents. The appeals court ruling in favor of Regenxbio emphasizes the intricate nature of patent law in biotechnology, where innovations often intersect with naturally occurring biological processes. This decision not only solidifies Regenxbio's intellectual property but also sets a precedent for future patent disputes within the sector.On the regulatory front, Vanda Pharmaceuticals has rebounded from previous setbacks by securing FDA approval for drugs targeting bipolar disorder and schizophrenia. This achievement marks a promising shift for Vanda, demonstrating resilience and adaptability in redirecting focus towards neuropsychiatric conditions. The approval expands therapeutic options for these complex disorders, addressing long-standing unmet needs within mental health care.Despite these advancements, some areas continue to face hurdles. Gene therapies like Casgevy and Lyfgenia for sickle cell disease have struggled to gain traction two years post-launch. These therapies promise a one-time cure by correcting genetic defects but have encountered challenges in achieving widespread adoption. The difficulties reflect broader issues in transitioning from clinical success to market viability.Moreover, workforce reductions at major companies such as Bristol-Myers Squibb and Catalent signal structural changes within the industry. These layoffs may indicate shifts in strategic focus or responses to evolving market pressures as companies strive for efficiency and innovation.Regulatory practices are also undergoing scrutiny as the FDA considers defaulting to single clinical trial requirements for drug approvals. While this move could streamline development processes, it raises concerns about maintaining rigorous safety standards—a balance that remains crucial as companies push to bring innovative treatments to market swiftly yet safely.The dynamic nature of this industry is further highlighted by Candel Therapeutics' recent $100 million royalty deal aimed at launching its prostate cancer treatment. This strategic move underscores growing interest in innovative oncology solutions thaSupport the show

Erick, Rock, Carcará, Batata, Coptulio, Miqueias, Villas Boas e Paganotto se reúnem para o Fala Glauber News. O programa vai ao ar segundas, quartas e sextas, das 16h00 às 20h00.QUER FAZER PARTE DISSO? ENTÃO BOOORAAA. VEM COM A GENTE E INTERAJA NESSA TRANSMISSÃO AO VIVO!!!VIIIIIIIIBRA!!! INSCREVA-SE NO NOSSO NOVO CANAL:  @falaglaubernews  CONHEÇA MAIS DOS NOSSOS PATROCINADORES:

This month, the gals welcome back their pal Robbie Knutsen to scream about mermaids in public, niche children's birthday party themes, Pentagon plugs, twisted panties, crocodile tears, and modern grave robbing. Tune in for February's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.   0:00 Introduction 11:26 Headlines 45:24 Coven Confessions 1:16:15 Coroner Corner

…ON TODAYS PROGRAM…   FERNANDO AND THE HONDA CURSE, LAWRENCE STROLL SELLS ASTON MARTIN NAMING RIGHTS FOR 50 MILLION POUNDS. FERRARI ON THE OTHER HAND SHOW OFF NEW SPINNING REAR WING AND, LOOK VERY COMPETITIVE ! MCLAREN AND MERCEDES ARE NOT FAR BEHIND… RED BULL IS STILL A QUESTION MARK?…AND FERNANDO WILL NEED HIS CAMPING CHAIR AS THE GP2 ENGINE THAT FAILED HIM AT MCLAREN, THAT WENT KABLAMO IN THE INDY 500 AND LOOKS TO HAUNT ALONSO FOR ANOTHER LONG SEASON!! STAY TUNED FOR SOME GREAT ONE LINERS FROM MACHISMO… THIS WEEK'S NASIR HAMEED CORNER…MORE VINTAGE BANTER BETWEEN THE HOST AND NASIR…THIS WEEKS SPECIAL GUEST: MARCUS ERICSSON, MARTIN BRUNDLE, AND MIKI MONRAS DE ESPANA…! Indianapolis 500 Veteran Hucul Dies at 79   INDIANAPOLIS (Friday, Feb. 20, 2026) – Canadian driver Cliff Hucul, a veteran of three Indianapolis 500 starts in the late 1970s, died Feb. 17 on his farm in his native Prince George, British Columbia. He was 79. Hucul made three consecutive starts in “The Greatest Spectacle in Racing” from 1977-79. His best finish came as a rookie in 1977, 22nd in the No. 29 Team Canada McLaren/Offenhauser that Hucul bought after Johnny Rutherford drove it to victory in the 1976 “500.” Hucul completed 72 laps before being sidelined by gearbox problems. He qualified on Bump Day for that race despite touching the wall in practice the previous day and suffering two engine failures during the Month of May, a significant pitfall for his low-budget team. Hucul's best qualifying spot was 18th in 1979, his final “500” start. The small-town driver from northern British Columbia learned his craft by racing stock cars and modified sprint cars at local tracks. He then began racing modifieds and supermodifieds in the Pacific Northwest against drivers that included eventual Indianapolis 500 winner and INDYCAR SERIES champion Tom Sneva and his brother Jerry Sneva. Hucul made 24 total USAC and CART starts between 1977-81, with eight top-10 finishes. Hucul's best finish in the standings was 11th in 1979, when he started the season by placing fifth at Ontario Motor Speedway and a career-best fourth at Texas World Speedway. In 1996, Hucul became a paraplegic after an automobile accident when crossing black ice on a highway in British Columbia. Despite being confined to a wheelchair, Hucul remained active, managing his farm and mentoring many drivers in the area. He was inducted into the Prince George Sports Hall of Fame for his lifetime contributions to auto racing. Hucul is survived by his son, Kelly, and daughter-in-law, Sylvie; daughter, Michele, and many grandchildren. 2026 BAHRAIN TESTING - WEEK 1, DAY 3 MAX VERSTAPPEN “Looking at the test overall, the Team got in a good number of laps on the first day so we were happy with that. We completed a lot of things that we wanted to test with the new Power Unit and the car in general. Today it was a continuation of that plus also trying to explore a little bit more with the car; you go through so many test items that it continues to change and evolve with everything that you are testing. In general, it is all so new that we are still learning a lot, but the car was good. We also have new tyres, so we spent some time looking at different sets and understanding what we need to improve and be better at. With the power unit, looking at the laps we got on the board, the start that we have had is good. That's exactly what we wanted to do and it was not a given. Whether it will be enough to win races, we don't know, we will just focus on ourselves and try to do the best we can, but there is still massive room for improvement. Finally, with the car, we learnt a lot about what worked and what didn't. Our runs also gave us even more ideas for the afternoon with Isack and then for next week, where we can continue to try new things and different set ups.” ISACK HADJAR “The first week here in Bahrain has gone well. Of course, I had to wait a little before getting in the car after Barcelona, but once I did, we were able to put it to the test and really work through what we need ahead of next week and Melbourne. There are so many things to look at, but we're staying on track with our programme so far. True performance and pace are always hard to judge in pre-season, but we can be happy with the reliability we've had from the power unit this week. There are still things to work on in terms of balance and tyre management, but that's completely normal for this time of year. We're working through it together as a Team to get where we want to be for Australia. I've known the people here for a while now, but it's great to be working with them again in an environment like this." ASTON MARTIN The Aston Martin Aramco Formula One™ Team concluded its testing programme at the Bahrain International Circuit today, with Lance Stroll returning to the cockpit of the AMR26 for the final time before the Australian Grand Prix. Lance did not get on track until late in the morning session due to a battery-related issue that had impacted Fernando's running yesterday. Honda carried out simulations on the test bench at HRC Sakura before the car returned to the track. Due to a shortage of power unit parts, the run plan was very limited and consisted only of short stints. Lance Stroll “It's been a challenging couple of weeks here in Bahrain, and today's limited running wasn't the way we wanted to finish the second test. It's clear the car isn't where we want it to be performance-wise, and we know there's a lot of work ahead in the coming weeks and months. There's a long season ahead, and we'll keep pushing flat out to unlock more performance. I want to say a big thank you to everyone trackside and back at the AMRTC for the work that's gone in so far. It's not where we want to be right now, but I know how determined this team is. We'll stick together, rise to the challenge and keep working until we deliver the performance we are looking for.” WILLIAMS F1 2026 Bahrain pre-season testing – Day 3 James Vowles, Team Principal: Another solid day of running and mileage. It's great to see that across the last six days of testing, we've been predominantly tyre and time limited, and able to complete the full programme that we wanted. That's just a testament to the hard work of the teams, both here and in Grove, making sure that we made up for lost time. 
 No one truly knows where all the performance lies. That's what Melbourne is all about, so I can't wait to go there, to gain a further understanding of where we are. What I know for sure, though, is we have work to do. There's no doubt about it. We've put ourselves on the back foot. But my assurance to everyone is that we have an aggressive programme lining up in front of us in order to make sure that we extract as much performance in this car as possible over the forthcoming months. Carlos Sainz: The past six days of testing in Bahrain has been one of the most interesting and challenging tests that I've been part of, given the new regulations and number of things we had to learn. The progress from day one has been significant, although there are still going to be things to understand and solve at the start of the season. We go into the first half of the year with lower expectations than 2025 knowing that we'll be starting slightly on the back foot. However, I'm really looking forward to getting started and focusing on improving the cars through the year to become more competitive. Bring on Melbourne! Alex Albon: It's been a relatively smooth test here in Bahrain. We got some good mileage under our belts and tested everything we wanted to get out of the car, so I'm feeling more ready for Melbourne. There's still a lot we need to understand and plenty of performance left on the table that we need to extract, but I'm glad the tests went to plan. It's now all about maximising the next few days to prepare for the first race of the year! THIS WEEK'S INTERVIEW WITH MIKI MONRAS... Miki Monrás on battling Bottas and Ricciardo in the late 2000s and the rising cost of junior racing In the late 2000s, Miki Monrás was one of Spain's brightest prospects on the junior single-seater ladder, trading blows with the likes of Daniel Ricciardo, Valtteri Bottas and António Félix da Costa in Formula Renault and GP3. But while his rivals pushed on towards F1 or careers in GTs, the Spaniard's single-seater journey came to an abrupt halt in 2011. Feeder Series caught up with Monrás to reflect on the times he rubbed shoulders with greatness, the challenges of racing in the post–financial crisis era, and life beyond motorsport. By Anabelle Bremner Back in the noughties, the path from karting to Formula 1 looked nothing like it does today. There was no standardised Formula 4, no carefully managed ladder – just a patchwork of championships that rewarded those brave enough, and wealthy enough, to dive straight in. Eurocup Formula Renault 2.0 was as deep as it got: 40-car grids stacked with future stars, the proving ground where Pierre Gasly, Nyck de Vries and Lando Norris would come to cut their teeth. But before all of them, it was Monrás in the thick of it. He made his single-seater debut in late 2007, the result of years spent chasing speed. His first taste of racing, in fact, came on two wheels – on a motocross bike, inspired by his father, who had raced professionally in Spain and Europe. At the age of eight, Monrás joined a motocross camp, and it wasn't long before karting came calling. “After the first race, I really enjoyed it,” he recalls. “I remember it was Christmastime and I asked for a motocross scooter and for a go-kart. So I finally got the go-kart, and that's the way I started. Then I started racing in Catalonia, and I just moved through Spain and Europe and all the world championships until formula.” Single-seater racing, however, would prove a unique beast. Shortly before turning 16, Monrás moved straight from karting into Formula Renault 2.0, in which the competition was fierce. “Normally at that age you'd go before to a category not straight to 2.0,” he said. “My first year I was racing with Bottas, I was racing with Ricciardo, I was racing with [Andrea] Caldarelli – really good drivers.… I was racing against people that were already racing for two years in single-seaters. That was a big difference.”His first Eurocup campaign, in 2008, proved a challenging one. He was scoreless for his first five rounds with the Hitech Junior Team (no relation to the current Hitech) before a switch to SG Formula brought him six points in the final two rounds. Valtteri Bottas, then of Motopark Academy, went on to claim that year's title after a close fight involving Ricciardo, Caldarelli and Roberto Merhi. The next year brought Monrás a decidedly better season and three podiums with SG Formula, owned by Mercedes Junior Team advisor Stéphane Guerin. He wound up fifth overall in a season dominated by a fierce three-way fight between Félix da Costa, Jean-Éric Vergne and Albert Costa – the last of whom ultimately took the title. Racing against so much talent at such a young age left Monrás with plenty of perspective on what might have been. “Ricciardo was my teammate. Jean-Éric Vergne was my teammate. I raced with Da Costa, Bottas, with Magnussen, so many people that have been racing each other and winning races,” he said. “[I] think if I changed something at that point, maybe I would be in Formula 1, but who knows. Maybe yes, maybe no. “But at that time, it was really difficult times because it was 2010, '11, '12, where there was also a big crisis in the world, especially in Europe. It was really difficult for Spanish drivers to get the sponsors and the money to race.” The financial squeeze triggered by the 2008 global financial crisis left Monrás and many of his peers in a precarious position. Several teams, such as SG Formula, shut their doors in the wake of the crisis amidst an already shifting landscape in junior racing. “It's been changing a lot from that time until now. When I was racing Eurocup 2.0, one time we were like 48 drivers, I remember. 2008 at Spa. It was a massive level and so many drivers wanted to go in,” he said. “Eurocup was really high level, I would say maybe [comparable] to Formula 4 about the car and the lap times. “Motorsport has changed a lot in the last few years. It's more expensive. At that time, Eurocup was also expensive, but I think Formula 4 is around €700,000 more or less, maybe more now. It's quite expensive. Back then, I think Eurocup was around €300,000 or €250,000, so there was a massive difference. A lot more people could race at that time.” After two and a half years competing in various Formula Renault series, Monrás stepped up to GP3 in 2010. The inaugural season, won by eventual F1 driver Esteban Gutiérrez, came with another steep learning curve. Monrás managed two podiums and a 10th-place finish in the standings, but the step up exposed the limits of what talent alone could achieve in a field packed with hungry, well-backed drivers. “When I raced GP3, that was the first year of the championship, so it was a new championship for all of the teams. I also raced with Arden, which was a new team in the category, so it made it a bit difficult,” he said. “During testing, I remember I was flying in GP3, and then suddenly in some races there was such a huge difference with some other cars and drivers. It was difficult sometimes. … I think this is always present in motorsport in all categories. You will find some kind of differences within cars and teams. It just will always be there.” Challenging as it was, that season had its highs for Monrás. A recovery drive in Spa's characteristic rain remains a fond memory for the Spaniard. “I had a really bad qualifying because there were some yellow flags,” he explained. “Because there were 30 cars, it was easy to find yellow flags if you're waiting for the last minutes in qualifying. I finished [ninth in] race one, and in race two it started raining really heavily after five laps. I went from P10 to P3, nearly fighting for the win in the last lap against Rossi and Tambay. That was a really good race.” After a season in GP3, Monrás moved up a rung on the ladder to Formula Two. At the time, the feeder series landscape was fragmented. GP2 and Formula Renault 3.5 offered established paths to Formula 1, while the MotorSport Vision's FIA Formula Two Championship, which first ran in 2009, aimed to do the same with a more affordable package. “Formula Two at that point was very competitive, economically speaking,” Monrás said. “It was a lot cheaper to race in Formula Two than race in GP2 at that moment or 3.5 because it was like all one team. All the cars were one team with different engineers, and that made it low cost for the time. “A lot of drivers went to it because of that. They were racing in the best tracks, same as World Series and similar to GP2, and the car was competitive. Maybe not as competitive as GP2 or 3.5 because it was a bit slower, but it was really competitive and really fast, on the straight especially.”  “In that time, what they were saying was it was very equal. You had one engineer for three cars, you were sharing data with these three cars, and it was all under the same team. You can always find differences in motorsport. Maybe not a difference to make one car win and one car P15, but you can still always find two-tenths difference in similar cars, and two tenths, sometimes it's a lot of time,” he said. “The cars were on the same team, but each engineer was doing the set-up for his driver. The set-up I was using and maybe the set-up Bortolotti was using, he had won the championship maybe from our different set-ups. Every race, you changed engineers. Every weekend, you were rotating engineers so at the end of the season, everybody worked with everyone.” By 2012, the funding had dried up. Monrás was left sponsorless and unable to compete in Formula Two. He sampled GT racing in the Blancpain Endurance Series and tested with both Audi Sport and Atech GP, but no program materialised. From there, Monrás transitioned into driver coaching and team management – mostly with the AV Formula team owned by his manager, Adrian Vallés – and eventually “moved on” from motorsport around 2017. “I was working also with McLaren Automotive, but it was not motorsport. It was automotive, developing road cars, really competitive cars. After that I decided to stop because I wanted to follow a new career professionally, and I moved onto real estate which I have always been [involved with] because of my family, so that's why I decided to move over,” he said. “I now work in a real estate company which I own with some partners, and that's my day-to-day nowadays.” After years climbing the ladder in lockstep with some of the sport's future stars, Monrás has found a new rhythm – one that's decidedly less fast, but no less his own. Yet his career remains a reminder of the talent that defined an era: a Spaniard who went wheel to wheel with the likes of Ricciardo, Bottas, and Vergne, racing in some of the deepest junior grids of the 2000s and 2010s. In the story of that generation, Monrás may no longer be on track, but he's never far from the memory of it all.

Narrativas analisa os acontecimentos do Brasil e do mundo sob diferentes perspectivas.     Com apresentação de #MadeleineLacsko, o programa desmonta discursos, expõe fake news e discute os impactos das narrativas na sociedade.     Abordando temas como geopolítica, comunicação e mídia, traz uma visão aprofundada   e esclarecedora sobre o mundo atual.     Ao vivo de segunda a sexta-feira às 17h.   Apoie o jornalismo independente. Assine O Antagonista e Crusoé com 10% via Pix ou Google Pay:   https://assine.oantagonista.com.br/   Siga O Antagonista no X:  https://x.com/o_antagonista   Acompanhe O Antagonista no canal do WhatsApp. Boletins diários, conteúdos exclusivos em vídeo e muito mais.  https://whatsapp.com/channel/0029Va2SurQHLHQbI5yJN344  Leia mais em www.oantagonista.com.br | www.crusoe.com.br #Janja #Lula #CartaoCorporativo #PoliticaBrasileira #GastosPublicos #NoticiasBrasil #GovernoLula #Transparencia #Economia #BrasilHoje #PortalDaTransparencia #JanjaLula #DinheiroPublico

Alexandre Garcia comenta sobre gastos do governo Lula, a necessidade de transparência no caso Master e maioridade penal. 

En este episodio del podcast de ACHO hematología, el Dr. Juan Manuel Herrera, especialista en Hematología y Oncología y coordinador de la Unidad de Trasplante de Médula Ósea y Terapia Celular de la Clínica Imbanaco en Cali, lidera este episodio dedicado a revisar los avances más relevantes en trasplante de médula ósea y terapias celulares. La dinámica del pódcast se centra en un recorrido histórico y actualizado de la especialidad, desde los primeros intentos de trasplante hasta las innovaciones más recientes en profilaxis y tratamiento de la enfermedad de injerto contra huésped (EICH), la expansión del pool de donantes, la integración de terapias génicas y la irrupción de las CAR-T. Se destaca el hito del E. Donnall Thomas, ganador del Premio Nobel por demostrar la curación de pacientes con anemia aplásica mediante trasplante, y cómo hoy el campo evoluciona hacia un modelo integral de terapia celular.En la conversación se abordan los cambios en la profilaxis de EICH con el uso de ciclofosfamida post-trasplante, que ha ampliado el acceso al trasplante alogénico incluso en donantes no emparentados; los avances terapéuticos con fármacos como ruxolitinib (a partir de los estudios REACH), belumosudil, itacitinib y abatacept; y la aprobación por la FDA de terapias innovadoras como células mesenquimales para EICH aguda pediátrica y terapias génicas para anemia de células falciformes en 2023. Asimismo, se analiza el papel de compuestos como UM171 en la expansión de sangre de cordón umbilical, la reducción de toxicidad en el acondicionamiento con treosulfán y la creciente integración de las terapias CAR-T en mieloma múltiple, linfoma y leucemia linfoide aguda, aclarando que no reemplazan el trasplante sino que lo complementan. Finalmente, se enfatiza cómo la mejora en soporte clínico, control infeccioso y experiencia de los equipos ha disminuido la mortalidad y ampliado las indicaciones, consolidando una práctica más segura y personalizada.Dentro de su conversación, se plantearon las siguientes preguntas:¿Cómo ha evolucionado el trasplante de médula ósea desde sus inicios hasta la actualidad?¿Qué impacto ha tenido la ciclofosfamida post-trasplante en la ampliación del pool de donantes?¿Cuáles son los avances más importantes en la profilaxis y el tratamiento de la EICH?¿Qué papel cumplen medicamentos como ruxolitinib, belumosudil, itacitinib y abatacept en la EICH?¿Qué relevancia tiene la aprobación de terapias génicas para anemia de células falciformes?¿Cómo ha influido el desarrollo de compuestos como UM171 en el trasplante con sangre de cordón umbilical?¿Qué ventajas ofrece el treosulfán frente a los esquemas clásicos de acondicionamiento?¿Las terapias CAR-T reemplazarán al trasplante o actúan como complemento?¿Cuáles son los principales riesgos actuales de las terapias CAR-T?¿Cómo han impactado estos avances en la supervivencia y calidad de vida de los pacientes?Fecha de grabación: 30 de septiembre de 2025.Referencia:Este contenido se basa en la interpretación crítica de la evidencia científica disponible, así como en la experiencia clínica del o los ponentes como profesionales de la salud en instituciones de referencia.Para profundizar en los conceptos discutidos, se recomienda al profesional de la salud consultar literatura científica vigente, guías clínicas internacionales y la normatividad aplicable en su país.

Produzida pela Coordenadoria de TV e Rádio do Superior Tribunal de Justiça (CRTV/STJ), reportagem especial apresenta um panorama dos entendimentos da corte sobre a atividade dos cartórios extrajudiciais no Brasil. .Entre os pontos abordados da jurisprudência do STJ, a matéria destaca precedentes envolvendo a configuração de nepotismo póstumo em nomeações e a definição do dever de divulgação de dados dos cartórios em portais da transparência do Poder Judiciário.

Dans cet épisode nous allons nous interroger sur les dilemmes et cas de conscience des managers.

Ever notice how your Etsy shop gets a lot of "Add to Cart" activity… but not a lot of purchases? You're not alone. In this episode, we break down why shoppers use "Add to Cart" so often in ecommerce , and why it doesn't mean they're ready to buy. Here is that creepy video I talked about - brace yourself. - https://www.youtube.com/watch?v=Ntf5_ue2Lzw&t=294s Join my skool group if your not too creeped out - https://www.skool.com/grow-my-etsy-shop-3051  

Álvaro Gribel, repórter especial e colunista do Estadão, comenta os principais assuntos da Economia e Política nacionais no Jornal Eldorado, às 2ªs, 4ªs e 6ªs, às 8h30.See omnystudio.com/listener for privacy information.

@katiucha e @OdeioPePe querem saber: você assumiria uma traição em rede internacional para ter seu paquera de volta? Se o crime não compensa, como uma cartãozeira ganhou medalha de ouro? Esse e outros questionamentos no episódio 113 do VortexOferta especial nos planos usando o nosso link no Nordvpn: https://nordvpn.com/vortexpodou CUPOM: VORTEXPODAcesse o link do Vortex e ganhe DESCONTO ESPECIAL  na sua matrícula na Alura: https://www.alura.com.br/vortexou CUPOM: VORTEX Host: Katiucha Barcelos. Instagram: @katbarcelos | Twitter/X: @katiuchaCo-Host: Pedro Pinheiro. Instagram: @odeiopepe | Twitter/X: @OdeioPePeInstagram: @feedvortexBluesky: @feedvortex.bsky.sociaTwitter: @feedvortexTiktok: @feedvortexReddit: r/feedvortexGrupo paralelo não-oficial do Vortex no telegram: https://t.me/+BHlkG92BfPU5ZjdhEsse grupo é dos ouvintes, para os ouvintes e pelos ouvintes. Não temos qualquer afiliação oficial ou responsabilidade por QUALQUER COISA falada neste grupoLink do post do episódio nas redes sociais:InstagramTwitterLinks comentados no episódio:Pronuncia do Sobrenome do LucasLucas Pinheiro cantando o hino do Brasil  Localização perfeita para uma olimpíada de inverno Acusação de trapaça vira polêmica no curling com xingamento e pedido de VARCurling: Canadá vive nova polêmica nos Jogos de Inverno de 2026 após acusação de trapaça no time masculinoVídeo da atleta canadense também SUPOSTAMENTE usando o dedinhoShaidorov se vestiu como Po , da franquia Kung Fu Panda, durante o evento de gala do Campeonato Mundial de 2025Rotina de Duna do medalhista de ouroAmericano dá mortal na patinação artistica, movimento que foi banido por anosNorueguês ganha medalha e confessa traiçãoResposta da NamoradaFugitivo eslovaco capturado quando tentou assistir hóquei olímpicoBatedora de carteira fa França leva ouroEstoque de camisinhas acaba na Vila Olímpica dos Jogos de Inverno, e 10 mil preservativos são repostos: 'Terminaram em 3 dias'Ex-atleta olímpica alemã revela por que há tantas relações sexuais entre atletas durante os Jogos OlímpicosProdução: Thyara Castro, Bruno Azevedo e Aparecido SantosEdição: Joel SukeIlustração da capa: Brann Sousa 

A study of II Samuel 6 on the importance of staying with God's Way and not going with worldly methods

Ecoutez L'édito d'Etienne Gernelle du 19 février 2026.Hébergé par Audiomeans. Visitez audiomeans.fr/politique-de-confidentialite pour plus d'informations.

AITA: For not giving someone my cart at Aldi's, DIRT ALERT: Gene Hackman estate update, an appreciation moment for "The Birdcage," and Jason's upcoming junket trip to Beverly HillsSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

recorded 1/21/2026

The Pre-Launch Strategy That Changes Everything What if your audience was already excited to buy before you ever opened the cart? That's the dream, right? No scrambling in the final hours. No sending more emails than you planned. No pushing harder than feels good and still wondering why it's not converting. I'm sitting down with Brenna McGowan, launch strategist and creator of Anticipation Marketing, to talk about the phase of launching most people skip over entirely. And honestly, it's the phase that makes or breaks your results. Here's what I've learned from my own launches and from watching thousands of my students do theirs: most people think they're doing the pre-launch part right. They mention what's coming in the P.S. of an email. They post about it on social and put up a waitlist. They feel like they're doing everything they're supposed to be doing. But then the cart opens and it still feels harder than it should. They're white-knuckling their way through launch week, and by the end of it, they're exhausted and wondering what went wrong. Is it the offer? Is it the audience? Is it just harder to sell right now? Usually, it's none of those things. It's the pre-launch. And that's what we're fixing today. RESOURCES MENTIONED IN THIS EPISODE: You've built something real. Revenue, audience, offers that work. But the results still don't match what you know you're capable of. The Revenue Consistency Formula is a FREE Live training for six-figure female founders who are done with inconsistent results and ready to understand what's out of sync so their messaging, offers, and lead generation can finally work together. Click here to register now. Learn More About Brenna McGowan Find Brenna McGowan on Instagram The Pre-Launch Plan Program HERE ARE THE 3 KEY TAKEAWAYS FROM THIS EPISODE: 1️⃣ A Waitlist Is Not a Pre-Launch — Posting "join the waitlist" isn't warming your audience up in the way you think it is. A real pre-launch builds belief in the problem, belief in the solution, and belief that you are the person to help them get there. When that's in place, you don't have to convince anyone when the cart opens. They're already in. 2️⃣ Sell the Process, Not the Program — During pre-launch, you shouldn't be talking about your course or your offer. Your job is to get your audience to believe in the method behind it. Brenna calls this belief-shifting, and it's the difference between an audience that's ready to buy and one that stays on the fence. 3️⃣ Anticipation Beats Urgency — Emphasizing the countdown used to work, but not anymore. People have been burned by courses and programs that didn't deliver, and they've lost trust in others and in themselves. What works now is building genuine excitement and curiosity so your audience is leaning in and asking when they can buy instead of feeling pushed into a decision. MORE FROM ME Follow me on Instagram @amyporterfield SUBSCRIBE & REVIEW If you loved this episode, please take a moment to subscribe and leave a review on Apple Podcasts! Your support helps us reach more entrepreneurs who need these insights.

What could replace chemotherapy?In this episode of Beyond the Rounds, we explore cellular therapy, CAR-T cell therapy, tumor-infiltrating lymphocytes (TIL), and how modern immunotherapy is reshaping cancer treatment. Dr. Nolan Fisher sits down with hematologist and cellular therapy specialist Dr. Yazan Samhouri of Banner MD Anderson Cancer Center to break down how immune-based cancer treatments differ from traditional chemotherapy — and why the “last resort” label for CAR-T is quickly becoming outdated.This episode is designed for physicians, advanced practice providers, and clinicians who want a practical understanding of where cellular therapies fit in today's oncology landscape.What We Cover:• The difference between chemotherapy, immunotherapy, and cellular therapy• How CAR-T cell therapy works (Chimeric Antigen Receptor T-cells explained)• Tumor-infiltrating lymphocyte (TIL) therapy for solid tumors• Stem cell transplant vs. CAR-T — complementary or competing?• Cytokine release syndrome (CRS) and neurologic toxicity• Patient selection and referral timing• Why earlier referral matters in relapsed/refractory disease• Next-generation CAR-T and multi-antigen targeting• Off-the-shelf cellular therapies and the future of accessKey Topics for Clinicians:Hematologic malignanciesLymphoma and leukemiaMetastatic melanomaRelapsed/refractory cancerBridging therapy during CAR-T manufacturingFDA-approved immunotherapiesCancer clinical trialsMultidisciplinary cancer careAbout Our GuestDr. Yazan Samhouri is a specialist in hematology and cellular therapy at Banner MD Anderson Cancer Center. His clinical focus includes CAR-T therapy, stem cell transplantation, and advanced immunotherapeutic approaches for blood cancers and select solid tumors.DisclaimerThis podcast is intended for educational purposes only and is designed for a clinical audience. Any patient scenarios discussed are modified and de-identified to protect privacy. No protected health information (PHI) is disclosed. The information presented should not replace independent medical judgment or individualized patient care decisions.Subscribe to Beyond the Rounds for physician-focused conversations on clinical innovation, specialty collaboration, and evolving standards of care.

Merci à Thomas !

On this episode Lara and Vyanka talk to Prof Georg Schett from Friedrich-Alexander University all about T cell engaging immunotherapies such as CAR T-cells and their use in the treatment of autoimmune diseases. This is ImmunoTea: Your Immunology Podcast, presented by Dr Lara Dungan and Dr Vyanka Redenbaugh. This is the show where we tell you all about the most exciting research going on in the world of immunology. So grab a cup of tea, sit down and relax and we'll fill you in. Contact us at ImmunoTeaPodcast@gmail.com or @ImmunoTea on twitter. Hosted on Acast. See acast.com/privacy for more information.

Almudena Grandes (Madrid, 1960-2021) ha sido una escritora extraordinaria, comprometida, una de las mejores narradoras de la última literatura española. Es la autora, entre otros, de 'Las edades de Lulú', 'Malena es un nombre de tango', 'Atlas de geografía humana', 'El corazón helado', 'Los aires difíciles' y de la extraordinaria serie 'Episodios de una guerra interminable', que dejó inacabada. 'Castillos de cartón' se publicó en el año 2004. 

La Universidad de Málaga acogerá una de las dos sedes en Europa de la IUPAC, la organización internacional que coordina y establece los estándares de la investigación química a nivel mundial. La elección de la ciudad andaluza pone fin a casi tres décadas de permanencia de la organización en Estados Unidos y sitúa a Málaga y a nuestro país como un lugar de referencia en la coordinación internacional de la Química. Hemos entrevistado a Javier García Martínez, expresidente de la IUPAC y gran artífice de esta decisión. Verónica Fuentes (SINC) nos ha hablado de los cazadores de eclipses, apasionados de la astronomía que siguen estos breves fenómenos por todo el mundo, y de la oportunidad que se les ofrece en nuestro país con sendos eclipses totales de Sol este año y el próximo, y un tercero anular en 2028. Con testimonios del chileno Alejandro Arroyo y del español Frank Rodríguez. El cloro es un elemento químico con una doble cara: es tóxico y, al mismo tiempo, fundamental para la vida. Bernardo Herradón nos ha contado sus aplicaciones médicas e industriales. Con Jesús Zamora hemos comentado tecnologías y proyectos disruptivos y prometedores que se anuncian, pero no que no terminan de llegar, como la computación cuántica o la colonización de otros mundos. Con Javier Ablanque al mando de nuestra máquina del tiempo hemos viajado a 1936, al frente de la Ciudad Universitaria en Madrid, donde se emplearon libros como parapetos, para conocer la física que hay detrás de un disparo de fusil. Hemos informado del premio Fundación BBVA Fronteras del conocimiento en la categoría de Biología y Biomedicina a Carl June y Michel Sadelain por revolucionar el tratamiento del cáncer a través de la inmunoterapia basada en la modificación genética de células del propio paciente, las llamadas células CAR-T.Escuchar audio

Autoimmune diseases like myasthenia gravis have long forced patients to trade daily function for chronic immunosuppression, but Cartesian Therapeutics is betting that its experimental RNA‑engineered CAR T cells can rewrite that equation. The company's lead experimental therapy, Descartes‑08, is designed to deliver deep, durable remissions through a short course of outpatient infusions that selectively eliminate the plasma cells driving disease, while sidestepping the toxicity and logistical hurdles of conventional DNA‑based CAR T therapies. We spoke to Carsten Brunn, CEO of Cartesian Therapeutics, about how the company's RNA‑engineered CAR T cells target the root cause of autoimmune diseases, data from its phase 2 study in myasthenia gravis, and the potential to expand the approach into myositis and other rare autoimmune indications.

The feature accepts both image and text prompts, but is still in beta at the moment. Learn more about your ad choices. Visit podcastchoices.com/adchoices

Early evidence for CAR T-cell therapy in lupus is compelling. Are you up-to-date? Credit available for this activity expires: 2/9/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/car-t-cells-sle-new-frontier-autoimmunity-2026a10003ow?ecd=bdc_podcast_libsyn_mscpedu

In this week's episode, Blood editor Dr. Laurie Sehn interviews authors Drs. Anastasios Karadimitris and Maria Carolina Florian on their papers published in Volume 147 Issue 2 of Blood. Dr. Karadimitris' paper "Off-the-shelf dual CAR-iNKT cell immunotherapy eradicates medullary and leptomeningeal high-risk KMT2A-rearranged leukemia", discusses the success of bispecific CAR-iNKT cells targeting CD19 and CD133 in pre-clinical models, prompting the clinical development of this class of product. Dr. Florian's paper, "A Notch trans-activation to cis-inhibition switch underlies hematopoietic stem cell aging" proposes that the Jagged2/Notch interaction is a key regulator of hematopoietic stem cell divisional symmetry during aging and offers insights that may inform strategies to restore regenerative function in aged hematopoiesis. 

Komórki nowotworowe to nie byty obce, ale nasze własne, tyle że zbuntowane.  Zamiast współpracować, odmawiają „honorowej” samodestrukcji (apoptozy), ignorują sygnały z otoczenia i dzielą się wtedy, kiedy nie powinny. – Komórka rakowa jest w sobie zakochana do tego stopnia, że interesuje ją tylko to, żeby siebie powielać – porównuje prof. Kinga Kamieniarz-Gdula z Centrum Zaawansowanych Technologii i Wydziału Biologii UAM w Poznaniu, z którą rozmawiam w najnowszym odcinku. Zdrowe komórki mają fizjologiczny limit podziałów. Po jego przekroczeniu przestają to robić lub umierają. – Natomiast komórki nowotworowe potrafią wyzerować ten licznik i stać się nieśmiertelne. Robią to często przez aktywację enzymu, który nazywa się telomeraza – wyjaśnia uczona. Takie komórki potrafią tworzyć własną sieć naczyń krwionośnych, omijają mechanizmy naprawy DNA i obronę immunologiczną.Słowem: są niezwykle trudnym przeciwnikiem. Mało kto jednak wie, że nowotwory powstają w nas bardzo często – organizm codziennie produkuje tysiące komórek z potencjalnie groźnymi mutacjami – ale zazwyczaj sobie z nimi radzi. Wchodzą do akcji „policjanci” układu odpornościowego, mechanizmy naprawy DNA. W rozmowie porządkujemy współczesne metody leczenia: od wciąż niezwykle skutecznej chirurgii, przez klasyczną chemioterapię i radioterapię, po nowsze terapie celowane oraz immunoterapię – w tym „żywy lek” CAR-T. Niedawno odkryto, że piętą Achillesową komórek rakowych jest końcowy etap przepisywania informacji genetycznej z genu (cząsteczki DNA) na RNA. Większość ludzkich genów ma kilka alternatywnych końców, a wybór tego właściwego może wpływać na końcowy produkt, czyli białko. Aby wykorzystać tę wiedzę w potencjalnej terapii przeciwnowotworowej, prof. Kinga Kamieniarz-Gdula wraz z dr Martyną Plens-Gałąską opracowały innowacyjną metodę do poszukiwań nowych leków, które kierują wyborem, gdzie kończy się gen. Uczone będą kontynuowały nowatorskie badania, m.in. dzięki kolejnemu grantowi ERC uzyskanemu przez prof. Kamieniarz-Gdulę, tym razem Proof of Concept, pozyskanemu na projekt “Biologia molekularna w terapii przeciwnowotworowej – poszukiwania nowych leków, które kierują wyborem, gdzie kończy się gen”. W zespole pracują wspólnie z dr Agatą Stępień.W odcinku usłyszycie też dlaczego sen, ruch, unikanie kancerogenów oraz ogólnie zdrowy styl życia naprawdę mają znaczenie – bo wspierają właśnie te ciche, codzienne interwencje naszego organizmu. Poznacie barwne metafory mechanizmów stojących za genetyką, opowieść o tym, jak to jest wrócić z Oxfrodu nad Wisłę, a także pochwałę badań podstawowych. Polecamy!W opisie wykorzystaliśmy fragmenty informacji prasowej Uniwersytetu im. Adama Mickiewicza. 

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into a series of transformative events shaping the landscape of drug development, regulatory scrutiny, and corporate strategies.At the forefront is Madrigal Pharmaceuticals' strategic acquisition of Ribo Therapeutics' preclinical siRNA programs, valued at $4.4 billion. This move aims to fortify Madrigal's liver disease drug portfolio alongside its promising candidate, resmetirom. By expanding into RNA-based therapies, Madrigal highlights an industry trend focused on gene silencing techniques to target genetic diseases more precisely.Turning to Moderna, it faces a regulatory hurdle as the FDA issued a refusal-to-file letter for its mRNA-based flu vaccine. The regulator's concerns about the trial design, specifically the use of a licensed standard-dose seasonal influenza vaccine as a control arm, emphasize the complexities of advancing mRNA technologies beyond COVID-19 applications. This situation underscores the necessity for meticulous trial designs that align with evolving regulatory standards.In cell therapy, allogeneic CAR-T treatments are gaining attention as companies strive to make these therapies more accessible by using T cells from healthy donors, rather than modifying a patient's cells. Despite technical challenges like graft-versus-host disease and immune rejection, these treatments promise streamlined manufacturing and reduced costs, marking a significant evolution from the pioneering autologous CAR-T success with Emily Whitehead in 2012. Eli Lilly's entry into CAR T-cell therapy through a $2.4 billion acquisition of Orna represents an ambitious expansion into autoimmune therapies. This strategic move exemplifies a broader trend where companies diversify portfolios to include emerging therapeutic modalities promising transformative impacts on patient care.In respiratory medicine, Upstream Bio's phase 2 trial of its TSLP receptor agonist showed encouraging results in reducing asthma exacerbations, comparable to Tezspire. However, falling short of best-case scenarios leaves room for competitors to present more compelling data. This illustrates the competitive nature of asthma treatment development and the ongoing quest for superior therapeutic options.A critical regulatory update arises from the NIH's decision to halt the Xarelto arm of a stroke prevention trial due to safety concerns. This decision highlights the indispensable role of independent monitoring committees in ensuring patient safety and meaningful clinical trial outcomes.On the corporate front, AstraZeneca has articulated an ambitious goal to achieve over 25 blockbuster drugs by 2030 as part of its strategy to reach $80 billion in revenue. This vision underscores the importance of innovation and strategic planning in sustaining growth within an increasingly competitive market.Fujifilm Biotechnologies' completion of its £400 million expansion project in the UK is another notable development, signaling robust investment in antibody production capabilities. This expansion positions Fujifilm as a key player in biopharmaceutical contract manufacturing and underscores the growing demand for flexible production technologies.The biotech sector is also witnessing significant activity with Pelage making strides in addressing hair loss through promising candidate developments. The market's enthusiasm for innovative solutions beyond traditional treatments reflects a broader demand for cutting-edge approaches to longstanding medical challenges.In obesity treatment, Novo Nordisk and Eli Lilly continue to lead with notable advancements. Novo Nordisk's recent developments with its Wegovy pill have been positively received, yet analysts question if this will suffice in maintaining their competitive edge given the dynamic nature of this therapeutic areSupport the show

Welcome to Impact Theory with Tom Bilyeu! In this eye-opening episode, Tom Bilyeu and co-host Drew tackle some of the most pressing—and controversial—headlines rocking the world this week. From Big Tech giants like Meta facing landmark lawsuits over the mental health impact of social media on kids, to explosive rumors about cancer cures being unleashed after the US's exit from the WHO, no stone is left unturned. Tom Bilyeu breaks down what's really behind these medical breakthroughs, debunking online conspiracies and explaining the critical roles of the FDA and Big Pharma. The conversation gets real about the unintended consequences of social media on developing minds, whether government intervention is the answer, and how parents can navigate the digital minefield. The hosts also deliver in-depth commentary on global power shifts, including China's economic maneuvers and Japan's political realignment, as well as the seismic advancements in AI technology that are set to reshape creative industries—and possibly life as we know it. To cap it off, Tom Bilyeu and Drew explore SpaceX's renewed focus on building a city on the moon, pondering what it means for humanity's future among the stars. Whether you're curious about the facts behind viral threads, anxious about the impact of tech on the next generation, or just want a fresh take on global headlines, this episode has something for everyone. Let's dive in! Quince: Free shipping and 365-day returns at https://quince.com/impactpodShopify: Sign up for your one-dollar-per-month trial period at https://shopify.com/impactKetone IQ: Visit https://ketone.com/IMPACT for 30% OFF your subscription orderIncogni: Take your personal data back with Incogni! Use code IMPACT at the link below and get 60% off an annual plan: https://incogni.com/impactBlocktrust IRA: Get up to $2,500 funding bonus to kickstart your account at https://tomcryptoira.comNetsuite: Right now, get our free business guide, Demystifying AI, at https://NetSuite.com/TheoryHuel: High-Protein Starter Kit 20% off for new customers at https://huel.com/impact code impact What's up, everybody? It's Tom Bilyeu here: If you want my help... STARTING a business: join me here at ZERO TO FOUNDER:  https://tombilyeu.com/zero-to-founder?utm_campaign=Podcast%20Offer&utm_source=podca[%E2%80%A6]d%20end%20of%20show&utm_content=podcast%20ad%20end%20of%20show SCALING a business: see if you qualify here.:  https://tombilyeu.com/call Get my battle-tested strategies and insights delivered weekly to your inbox: sign up here.: https://tombilyeu.com/ ********************************************************************** If you're serious about leveling up your life, I urge you to check out my new podcast, Tom Bilyeu's Mindset Playbook —a goldmine of my most impactful episodes on mindset, business, and health. Trust me, your future self will thank you. ********************************************************************** FOLLOW TOM: Instagram: https://www.instagram.com/tombilyeu/ Tik Tok: https://www.tiktok.com/@tombilyeu?lang=en Twitter: https://twitter.com/tombilyeu YouTube: https://www.youtube.com/@TomBilyeu Big Tech lawsuit, social media addiction, mental health, Big Pharma, cancer cures, World Health Organization (WHO), US healthcare, FDA, immunotherapy, mRNA cancer vaccines, CAR-T cell therapy, KRAS inhibitors, drug approvals, government incentives, socialism, AI breakthroughs, video AI, creative industry, China-US relations, de-dollarization, US debt, China demographics, Japan politics, sushi-fication of Japan, immigration, education policy, brain development, parental control, government regulation, space exploration, Elon Musk moon base. Learn more about your ad choices. Visit megaphone.fm/adchoices

Synopsis: At the heart of JPM 2026's biotech buzz, Alok Tayi sits down with Fred Aslan, CEO of Artiva, to explore how bold platform bets, scalable cell therapies, and autoimmune breakthroughs could reshape medicine. Fred traces his journey from medical school in Brazil to consulting at BCG, venture capital, and ultimately founding multiple companies—sharing why following curiosity, not rigid career ladders, shaped his path. Fred dives deep into the bottlenecks holding back traditional CAR-T therapies—manufacturing complexity, cost, hospitalization, and toxicity—and explains how Artiva's off-the-shelf NK-cell platform aims to change the paradigm. The discussion explores why rheumatoid arthritis became Artiva's lead indication, how immune “resets” could redefine autoimmune care, and what's ahead in 2026 as the company prepares registrational trials and expands its basket studies across lupus, myositis, scleroderma, and more. The episode closes with rapid-fire takes on AI in drug development, China's accelerating biotech engine, rare disease trial models, and the strategic principles founders should follow when choosing indications and building durable platforms. Biography: Fred Aslan, M.D., has a 20-year track record as an executive and investor in the life sciences industry. He was most recently President and CBO at Vividion Therapeutics, where he was responsible for business development, finance, alliance and project management, and operations. Dr. Aslan had the opportunity to lead Vividion's Series B financing and $135M-upfront collaboration with Roche. Prior to Vividion, Dr. Aslan had a 12-year affiliation with Venrock. Initially he was an investor from 2006 to 2013, when he cofounded and served as a board member of Receptos Pharmaceuticals (acquired by Celgene for more than $7 billion). Dr. Aslan led Venrock's investment in Zeltiq (acquired by Allergan for more than $2 billion) and was involved in the early formation of Fate Therapeutics. Subsequently as an entrepreneur from 2013 to 2018, he was CEO of Adavium Medical, a Brazilian medical device company, which he grew from zero to 350 employees, sales of over US$40 million, and fully integrated R&D, manufacturing, and commercial capabilities. Prior to Venrock, Dr. Aslan was Director of Business Development and Head of Investor Relations for CuraGen, a Nasdaq-listed oncology-focused biotech company. Prior to CuraGen, he was a consultant at Boston Consulting Group (BCG). Dr. Aslan holds a B.S. in biology from Duke University, an M.D. from Yale School of Medicine, and an MBA from Harvard Business School.

Is Artificial Intelligence actually helping cancer patients, or is it just noise? In this episode of The Patient From Hell, Samira sits down with Dr. Shadi Nabhan to separate the Hype from the Reality in 2026.We discuss the massive evolution in oncology—from the "library days" of 1995 to the AI-driven diagnostics of today. Dr. Shadi shares his "Airport Analogy" for navigating a cancer diagnosis, offers a life-changing reframe on how we view advanced disease (it's not just "curable" vs. "terminal"—it can be "controllable"), and gives his #1 piece of advice for selecting a medical team that will actually show up for you when things get hard.Key Topics Discussed:AI in 2026: How doctors use AI to simplify complex terms like CAR T-cell therapy and why patients need to "trust but verify" AI-generated medical advice.The "Controllable" Reframe: Why treating metastatic cancer like diabetes or hypertension changes the patient experience.Navigating the "Airport": Why the healthcare system feels like being dropped in a foreign airport without a map.Advice for the Industry: What Healthcare Systems and Pharma companies need to change right now regarding clinical trials and drug pricing.About Today's Guest Dr. Chadi Nabhan:Dr. Chadi Nabhan is a board-certified hematologist, oncologist, and the Chief Medical Officer at Ryght, Inc., where he leads the integration of Generative AI into clinical research to accelerate the delivery of lifesaving therapies. With a career spanning leadership roles at Caris Life Sciences and the University of Chicago, Dr. Nabhan is a prolific researcher with over 300 publications and a prominent author whose work focuses on the intersection of medicine, justice, and technology.AI Visionary: Leading the charge in using AI to optimize clinical trials and patient outcomes.Expert Clinician: Trained at Northwestern and Harvard, with decades of experience in malignant hematology.Renowned Author: Published three books with Johns Hopkins University Press, including The Cancer Journey and the forthcoming AI and Cancer Care (2026).Podcast Host: Voice of the popular weekly series Healthcare Unfiltered.Quotes from the Episode:"We cure more patients than we have ever dreamt of... Women who are affected by breast cancer today are more likely to be completely cured." "Availability is key. Are they going to really pick up the phone and talk to you when you need them?"00:00 - The reality of the cancer journey (It's not smooth sailing)01:00 - Intro: Dr. Shadi Nabhan & The Fun Factor01:25 - AI in Healthcare: Hype, Hope, and Reality04:15 - How doctors use AI to explain complex therapies06:38 - Warning for patients using AI: "Garbage in, Garbage out"08:45 - The Evolution of Medicine: 1995 vs. 202613:00 - The "Airport Analogy": Why patients feel lost17:30 - MUST WATCH: Reframing "Terminal" cancer as "Controllable"21:30 - Advice for Healthcare Leaders: Agility & Patient Involvement23:50 - Advice for Pharma: Drug Pricing & Accelerating Innovation26:00 - The #1 criteria for picking your medical team28:18 - The importance of Second Opinions28:50 - What to expect in late 2026: AI in Cancer Care Book

In the ever-evolving world of implement technology, a Saskatchewan-based company is looking to clear things up for growers. At the Western Canadian Crop Production Show in Saskatoon, Sask., Brad Reykdal of AgVision joined RealAgriculture’s Amber Bell to discuss AgVision HD. This digital implement camera system was designed to address a void in the Canadian agricultural... Read More

As cell and gene therapies continue to deliver promising clinical results, manufacturing remains one of the biggest barriers to broader commercialization. Persistent challenges around cost, complexity, labor intensity, and vein-to-vein timelines—particularly for autologous CAR-T therapies—are limiting the industry's ability to scale beyond niche and last-line indications. Addressing these constraints will be critical if CGTs are to move earlier in treatment paradigms and reach more patients globally. In this episode of Off Script, we spoke with Jon Ellis, CEO of Trenchant BioSystems, about the current state of cell and gene therapy manufacturing and where the industry must go next. The conversation explores why traditional centralized manufacturing models are struggling to scale, how automation and digital batch records can significantly compress manufacturing timelines, and how emerging platforms are rethinking cell recovery, analytics integration, and starting material strategies.

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we're diving into a range of stories that highlight the dynamic and often challenging landscape of these industries, as they navigate through scientific breakthroughs, strategic collaborations, regulatory hurdles, and market trends.Starting with corporate restructuring, Roche's Genentech has announced significant layoffs, totaling 489 positions in the previous year. This move is part of broader restructuring efforts seen across large pharmaceutical companies like Bayer and Bristol Myers Squibb. The layoffs illustrate the tightening financial and scientific constraints that are influencing pipeline decisions and capital allocation. Companies are facing increasing pressures to maintain credibility while also dealing with economic challenges that impact their strategic directions.On the regulatory front, the U.S. Department of Health and Human Services (HHS) encountered legal setbacks concerning its 340B rebate model pilot program. Following a lawsuit from the American Hospital Association, HHS withdrew notices and application approvals for this initiative. This development indicates a need for more comprehensive public feedback before any future attempts at similar programs are made, highlighting how complex regulatory landscapes can become.Turning to clinical trials, Fierce Biotech identified several significant failures in 2025, underscoring the inherent risks involved in drug development. These setbacks emphasize the importance of robust trial designs and execution strategies to mitigate risks. Meanwhile, Fresenius Kabi and Phlow Corporation have announced a strategic alliance to produce epinephrine injection API in the U.S., aiming to strengthen supply chain resilience—a crucial lesson learned from vulnerabilities exposed during the COVID-19 pandemic.Eli Lilly has made waves with its $2.4 billion acquisition of Orna Therapeutics, marking its entry into the in vivo CAR-T space. This acquisition underscores a growing interest in advanced cell therapies with transformative potential for cancer treatment. Additionally, Lilly has expanded its collaboration with Innovent Biologics through a $350 million upfront payment and milestone payments totaling $8.8 billion, focusing on oncology and immunology. This reflects a shift towards deeper integration in drug development efforts beyond traditional licensing models.Takeda Pharmaceuticals' $1.7 billion AI-driven drug discovery agreement with Iambic Therapeutics highlights the increasing adoption of artificial intelligence to accelerate drug discovery processes. AI's potential to enhance precision medicine approaches is becoming more pronounced as companies seek innovative methods to improve target identification and lead optimization.In market dynamics, Hims & Hers withdrew from launching a generic version of Novo Nordisk's weight loss pill due to regulatory pressures from the FDA. This incident underscores the complex interplay between innovation and compliance that companies must navigate when bringing new therapeutics to market. Additionally, legal actions have been initiated by Novo Nordisk against Hims & Hers over patent infringement claims related to semaglutide—a case highlighting ongoing challenges in patent protection within rapidly evolving drug compounding arenas.Eli Lilly also leveraged the global stage of the Winter Olympics for a campaign drawing parallels between scientific progress and athletic achievement. Such campaigns align with industry efforts to enhance public perception and trust amid ongoing challenges.Overall, while the pharmaceutical and biotech industries face significant challenges—from regulatory hurdles to clinical trial setbacks—there are substantial opportunities for growth driven by technological advancements and strategic collaborations. NaSupport the show

We love to hear from our listeners. Send us a message. On this week's episode of the Business of Biotech, we're speaking with Cindy Perettie, Executive Vice President and Global Head at Kite Pharma, a Gilead-owned company focused on curing cancer with cell therapies. Perettie talks about scaling cell therapies in the community setting, global manufacturing strategy, preparing for the launch of late-stage development programs in lymphoma and multiple myeloma, and working with partners like Arcellx. She also discusses cell therapy funding cycles and big pharma, the autologous versus allogeneic divide, why in vivo CAR-T therapies could be a game changer, what the FDA's focus on cell and gene therapies could mean for U.S. competition, and more. Access this and hundreds of episodes of the Business of Biotech videocast under the Business of Biotech tab at lifescienceleader.com. Subscribe to our monthly Business of Biotech newsletter. Get in touch with guest and topic suggestions: ben.comer@lifescienceleader.comFind Ben Comer on LinkedIn: https://www.linkedin.com/in/bencomer/

Aujourd'hui, Joëlle Dago-Serry, coach de vie, Bruno Poncet, cheminot, et Jean-Loup Bonnamy, professeur de philosophie, débattent de l'actualité autour d'Alain Marschall et Olivier Truchot.

Race Industry Week Day One closed with a powerhouse guest: Danny Sullivan — 1985 Indianapolis 500 winner, 1988 CART Champion, former Formula 1 driver steward, broadcaster, and one of motorsport's greatest storytellers.In this candid, wide-ranging conversation hosted by Brad Gillie, Sullivan shares a lifetime of experience from behind the wheel, inside F1 race control, across IndyCar and CART legends, and through decades of mentoring young talent.

Ready to make 2026 the year your route runs smoother, faster, and with less strain? We're sharing the exact tools that pay you back in minutes saved and backs spared, plus how to pick the right version for your truck, your clients, and your local conditions.We start with the true workhorse: your pole. Carbon fiber has become the smartest upgrade for daily service thanks to its lighter weight, stiffness, and durability. You'll hear how Primate's vertical lever locks and 3-piece reach let you cover most pools from one side while fitting comfortably in short beds. Then we break down the vacuum landscape. Riptide and Hammerhead remain the heavy hitters with reliable carts and power, but cordless heads like the Bottom Feeder and Shrimp now level up with a cartridge filter assembly that captures dirt down to fine microns while still gobbling leaves. If you want less setup and more clean, this change is a big win.Next, we get practical about skimming and testing. The Piranha 2 quick-flip leaf rake edges out the Red Baron for its balanced lip and easy dumps that save precious seconds on every basket-empty day. For water chemistry, the LaMotte ColorQ 2X Pro 9 delivers photometer accuracy without Spin Touch pricing, and crucially adds copper and iron testing to diagnose staining and metals from fill water. We also cover a field favorite: the Multi-Torque socket set that turns stubborn filter lids into a quick drill job and keeps knuckles intact, plus the glove setup that protects hands year-round—light nitrile-coated pairs for daily work and long-cuff Atlas 772s for cold mornings.• Carbon fiber poles with fast vertical locks and smart sizing• Cart vacs vs cordless heads for debris and dirt pickup• Bottom Feeder and Shrimp with cartridge filter assembly• Leaf rakes compared: Piranha 2 quick-flip vs Red Baron• Photometry: ColorQ 2X Pro 9 vs Spin Touch use cases• Multi-Torque sockets for faster, safer filter service• Hand protection: nitrile-coated gloves and cold-weather picks• Discounts and part numbers to make buSend us a textSupport the Pool Guy Podcast Show Sponsors! HASA https://bit.ly/HASAThe Bottom Feeder. Save $100 with Code: DVB100https://store.thebottomfeeder.com/Try Skimmer FREE for 30 days:https://getskimmer.com/poolguy Get UPA Liability Insurance $64 a month! https://forms.gle/F9YoTWNQ8WnvT4QBAPool Guy Coaching: https://bit.ly/40wFE6y

Broadcast from KSQD, Santa Cruz on 3-05-2026: >ul> Dr. Dawn presents a whimsical "theme park tour" of the upper gastrointestinal tract, from saliva production triggered by sight and smell of food, through the esophageal sphincter's iris-like opening, into the stomach's pH-1 acid bath where parietal cells produce 3,000 mg of hydrochloric acid per meal. She explains protective mechanisms including the bicarbonate layer beneath stomach mucus, H. pylori's role in ulcers, and how H2 blockers and proton pump inhibitors work—cautioning about long-term PPI effects on B12 and calcium absorption. The tour continues through the pylorus into the duodenum where pancreatic enzymes and bile converge, then along the 23-foot small intestine with its tennis-court surface area of villi absorbing nutrients, iron in the duodenum, most nutrients in the jejunum, and B12 requiring intrinsic factor in the ileum. Dr. Dawn explains why pancreatic cancer—projected to become the second leading cause of cancer death by 2030—is so deadly, using a medieval castle metaphor. The tumor microenvironment acts as an impenetrable moat of desmoplastic stroma made of fibroblasts, collagen, and hyaluronic acid that blocks drugs and immune cells. Over 90% of cases have K-RAS mutations acting as growth accelerators that also thicken this protective barrier and increase CD47 "don't eat me" signals. She discusses emerging treatments including K-RAS inhibitors, PARP inhibitors for BRCA mutations, and combination immunotherapies showing 67% response rates, while noting that CAR T-cell therapy and checkpoint inhibitors alone fail because they cannot penetrate the stroma. Dr. Dawn summarizes Duke researcher Herman Ponzer's work using doubly-labeled water to measure total energy expenditure, revealing that humans burn 20-60% more calories than other great apes when adjusted for body mass. His surprising finding: Hadza hunter-gatherers walking 8-14 kilometers daily burn the same calories as sedentary Americans—the body compensates by reducing energy spent on inflammation and stress responses. This "constrained energy expenditure" model explains why exercise alone doesn't cause weight loss, though it remains crucial for preventing weight gain, reducing disease risk, and potentially tamping down harmful stress responses.

The Grocery Cart Theory reveals how real leadership shows up in small, untracked moments where integrity and empathy operate without incentives. This episode explores why the best leaders do the right thing even when no one is watching.Host: Paul FalavolitoConnect with me on your favorite platform: Facebook, Twitter, Instagram, TikTok, LinkedIn, Substack, BlueSky, Threads, LinkTree, YouTubeView my website for free leadership resources and exclusive merchandise: www.paulfalavolito.comBooks by Paul FalavolitoThe 7 Minute Leadership® Handbook: bit.ly/48J8zFGThe Leadership Academy: https://bit.ly/4lnT1PfThe 7 Minute Leadership® Survival Guide: https://bit.ly/4ij0g8yThe Leader's Book of Secrets: http://bit.ly/4oeGzCI

Dr. Jeni Hayes, Senior Clinical Manager, Strategic Clinical Intelligence, and Dr. Heather Pace, Senior Clinical Manager, Ambulatory Care, join host Carolyn Liptak to discuss the Vizient Winter 2026 Spend Management Outlook, with a focus on pharmacy projections and key changes from prior outlooks. The episode also covers ambulatory care and self-administered drugs, biosimilar therapeutic insights, and dynamic pharmacy market forces.   Guest speaker:     Jeni Hayes, PharmD, BCPS   Senior Clinical Manager, Strategic Clinical Intelligence Vizient Spend Management Solutions   Heather Pace, PharmD   Senior Clinical Manager, Ambulatory Care Vizient Center for Pharmacy Practice Excellence     Host:   Carolyn Liptak, MBA, BS Pharm Pharmacy Executive Director, Regulatory Compliance & Revenue Integrity Center for Pharmacy Practice Excellence (CPPE) Vizient   00:05 — Introduction Announcer welcomes listeners to Verified Rx, produced by the Vizient Center for Pharmacy Practice Excellence.   00:14 — Episode Overview Host Carolyn Liptak, Pharmacy Executive Director at Vizient, introduces the Winter 2026 Spend Management Outlook (SMO). Focus areas: Pharmacy inflation projections Acute vs ambulatory care trends Provider-administered vs self-administered drugs Biosimilar therapeutic insights Dynamic pharmacy market forces shaping 2026–2030 Guests: Jeni Hayes, Senior Clinical Manager, Strategic Clinical Intelligence Heather Pace, Senior Clinical Manager, Ambulatory Care   01:09 — What Is the Spend Management Outlook (SMO)? Biannual Vizient publication projecting price trends across healthcare spend categories. Pharmacy headline: Inflation slightly lower than last edition Total spend still rising, driven by utilization growth and new technologies   01:49 — Top-Line Pharmacy Inflation Projection 2.84% projected drug inflation for purchases between July 2026 – June 2027. Down from 3.35% in the prior edition. Based on October 2024 – September 2025 wholesaler data. Heavily weighted toward highest-spend drugs. Contracted products show lower inflation; non-contract drugs still ~70% of spend.   02:45 — Inflation by Site of Care Acute Care 3.03% projected inflation Driven by: Sugammadex Kcentra Clotting factors Ambulatory Care 2.85% overall, but with key divergence: Provider-administered drugs: 3.35% Self-administered drugs: 2.43%   04:02 — Provider-Administered Drugs: What's Driving Growth Oncology infusions are the main drivers. Key agents: Keytruda Darzalex Faspro Continued growth due to: Expanded indications Increased outpatient infusion utilization Oncology split by site of care: Inpatient: High-cost CAR T (e.g., Yescarta) Outpatient: Infusions, bispecifics, emerging cellular therapies Emphasizes importance of site of care strategy.   05:14 — Self-Administered Drugs: Utilization Over Inflation Five key drivers: Autoimmune / inflammatory: Skyrizi, Dupixent, Rinvoq Diabetes / metabolic / weight loss: Ozempic, Wegovy, Mounjaro, Zepbound Spend growth fueled by: Media exposure Expanded indications Increased patient demand Opportunity for: Retail & specialty pharmacy optimization Margin capture Patient support (adherence, counseling, benefits investigation)   06:45 — New Section: Dynamic Pharmacy Market Forces (2026–2030) Seven strategic forces influencing pharmacy practice: Growth in specialty and cell & gene therapies Expansion of value- and outcomes-based contracting Siteofcare shifts toward ambulatory and home Digital transformation & automation Supply assurance and resilience Expanded pharmacist clinical scope & workforce models Regulatory and policy efforts to lower drug prices 340B changes IRA Medicare Part D negotiations   09:37 — Practical Takeaways for Pharmacy Leaders Use 2.84% inflation as a baseline — then customize using Vizient Pharmacy Analytics. Leverage segmented views to prioritize: Acute vs ambulatory strategies Provider-administered vs self-administered drugs Identify top spend movers and align them with long-term market forces. Consider: Specialty pharmacy expansion Site of care optimization   10:48 — Biosimilar Therapeutic Insights: 2025 Recap Heather Pace highlights: Shift from biosimilar approval to active adoption management. Ustekinumab (Stelara) as defining example: Multiple biosimilars Uptake driven by payer and PBM strategy Utilization varies widely based on: Formulary design Benefit alignment Biosimilars now actively steered, not passively adopted.   11:50 — Why Stelara Was a Turning Point PBM-developed, private-label biosimilars drove adoption. Net cost and copay design outweighed: Interchangeability status Manufacturer differentiation Sets expectations for future biologic launches.   12:25 — Operational Impact for Health Systems Expect payer-specific product preferences. Frequent switching will become routine. Key considerations: Siteofcare mandates Product presentation Supply chain logistics Billing & reimbursement complexity Clinical barriers are decreasing; workflow flexibility is critical.   13:09 — What to Expect From Biosimilars in 2026 Faster adoption timelines Earlier payer-driven switching Fewer preferred products Less reliance on reference product trial periods   13:45 — Biosimilars With Major 2026 Impact Eylea — multiple launches expected post-litigation Xolair — expansion into asthma/allergy and retail specialty Perjeta — oncology pathway disruption expected late 2026 / early 2027   15:01 — 2025 Biosimilars Impacting 2026 Ustekinumab (Stelara): broader formulary shifts Denosumab (Prolia, Xgeva): full year of impact; all interchangeable Eculizumab (Soliris): first rare-disease biosimilar entry   15:58 — FDA Biosimilar Guidance to Watch Late-2025 FDA guidance: Reduced reliance on clinical efficacy trials Greater emphasis on analytical similarity Aims to: Reduce development cost Accelerate market entry   16:26 — Interchangeability: Where Things Are Headed Moving toward expectation that all biosimilars are interchangeable. Shifts responsibility to: Payers Health systems Pharmacists managing transitions and education   17:17 — Biggest Shift in the Biosimilar Landscape Faster launches Larger scale adoption Payer strategy more influential than timing of approval Success depends on: Formulary fit Channel alignment Operational simplicity   17:41 — Final Biosimilar Insight Biosimilar strategies must be molecule-specific. One-size-fits-all approaches are no longer effective.   18:13 — Final Thoughts on the SMO Inflation projections are a starting point. Leaders should: Focus on top spend drugs Understand siteofcare and specialty drivers Translate projections into actionable budgets   18:40 — Resources Winter 2026 Spend Management Outlook available on Vizient's SMO Hub. Includes current and prior editions and related insights.   18:58 — Closing Carolyn thanks Jeni and Heather. Reminder to subscribe, like, and share feedback. Verified Rx is produced by the Vizient Center for Pharmacy Practice Excellence.   Links | Resources:  Vizient Spend Management Outlook webpage Vizient Winter 2026 Spend Management Outlook Vizient Biosimilars Therapeutic Insights   Subscribe Today! Apple Podcasts Spotify YouTube RSS Feed    

In this episode, Lyell K. Jones Jr, MD, FAAN, speaks with Aaron L. Berkowitz, MD, PhD, FAAN, who served as the guest editor of the February 2026 Neurology of Systemic Disease issue. They provide a preview of the issue, which publishes on February 2, 2026. Dr. Jones is the editor-in-chief of Continuum: Lifelong Learning in Neurology® and is a professor of neurology at Mayo Clinic in Rochester, Minnesota. Dr. Berkowitz is a Continuum® Audio interviewer and a professor of neurology in the Department of Neurology at the University of California, San Francisco, in San Francisco, California. Additional Resources Read the issue: continuum.aan.com Subscribe to Continuum®: shop.lww.com/Continuum Continuum® Aloud (verbatim audio-book style recordings of articles available only to Continuum® subscribers): continpub.com/Aloud More about the American Academy of Neurology: aan.com Social Media facebook.com/continuumcme @ContinuumAAN Host: @LyellJ Guest: @AaronLBerkowitz Full episode transcript available here Dr Jones: The human nervous system is so complex. You can spend your whole career studying it and still have plenty to learn. But the human brain does not exist in isolation. It's intricately connected with and reliant on other bodily systems. When those systems go awry, sometimes the first sign is in the nervous system. Today we will speak with Dr Aaron Berkowitz, an expert on the neurology of systemic disease, and learn a little about how these disorders can present and what we can do about it. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum. Thank you for listening to Continuum Audio. Be sure to visit the links in the episode notes for information about subscribing to the journal, listening to verbatim recordings of the articles, and exclusive access to interviews not featured on the podcast. Dr Jones: This is Dr Lyell Jones, Editor-in-Chief of Continuum: Lifelong Learning in Neurology. Today, I'm interviewing Dr Aaron Berkowitz, who is Continuum's guest editor for our latest issue of Continuum on the neurology of systemic disease. Dr Berkowitz is a professor of clinical neurology at the University of California, San Francisco, and he has an active practice as a neurohospitalist and in outpatient general neurology---and, importantly, as a clinician educator. In addition to numerous teaching awards, Dr Berkowitz has published several books and also serves on our editorial board for Continuum. Dr Berkowitz, welcome. Thank you for joining us. Why don't you introduce yourself to our listeners?  Dr Berkowitz: Thanks, Lyell. As you mentioned, I'm a general neurologist and neurohospitalist here in San Francisco, California at UCSF and very involved in resident education as well. And I was honored, flattered and a little bit frightened when I received the invitation to guest edit this massive issue on the neurology of systemic disease. But I've learned a ton, and it's been great to work with you and the incredible authors we recruited to write for us. And I'm excited to have the issue out in the world.  Dr Jones: Yeah, me too. And you and I have talked about it before: you're one of a very small group of people who have guest edited multiple issues on different topics, right?  Dr Berkowitz: That's right. I did the neuroinfectious disease issue in… was it 2020? 2021? Something like that.  Dr Jones: Yeah. So, congratulations, more people have walked on the moon than done what you've done. And I'm looking forward to chatting, Aaron, and really grateful for your work putting together a fantastic issue. I think our listeners will appreciate that the nervous system does not function in isolation. It's important to understand the neurologic manifestations of diseases that originate within the brain, spinal cord, nerves, muscles, etc., but also the manifestations of diseases that begin in other systems and, you know, may masquerade as a primary neurologic disorder. So, it's obviously an important topic for neurologists, since many of these patients are receiving care in another setting, perhaps from another specialist. I almost think of this issue of Continuum as a handbook for the consultant neurologist, inpatient or outpatient. I don't know. Do you think that's a fair characterization of the topic? Dr Berkowitz: Absolutely. I completely agree with you. I think, yeah, many of us go into neurology interested in our primary diseases, whether it's stroke or Parkinson's or neuropathy or particular interest in neurologic symptoms, whether they're cognitive, motor, sensory, visual. And we quickly learn in residency, right? As you said, a lot of what we see is neurologic manifestations of primary diseases. So, I don't know how similar this is to other training programs. But it seemed like, if I'm remembering correctly, my first year of residency was mostly on primary neurology services, general stroke, ICU. And we moved into the consultant role more in the PGY-3 year the next year. And I remember explaining to students rotating with us on the consult services, this is actually much more complex in a way, because the patient has some type of symptom in a much broader and much more complicated context of multiple things going on. And I call it "neurology in the wild." There's, like, neurology of, this patient's had a stroke and we know they have a stroke and we're trying to figure out why and treat it. That's all interesting. But our question here, is there a stroke needle buried in this haystack of all of these medical or surgical complications? And learning what I call neurology of X, which is really what this issue is; as you said, that there's a neurology of everything. There's a neurology of cardiac disease. There's a neurology of the peripartum. There's a neurology of rheumatologic disease. There's every new treatment that comes out in oncology has a neurology we learn, right? There's a neurology of everything.  Dr Jones: There's a lot of axes, right? There's the heart-brain axis and the kidney-brain axis. And… I think we cover everything except the spleen-brain axis, which maybe that's a thing, maybe not. I'll probably hear from all the spleen fans out there. So, I want to do a little bit of an experiment. We're going to do something new today on the podcast. Before we get into the questions, we're going to start with a Continuum Audio trivia question. So, this will be a first time ever. Dr Berkowitz, we all know that chronic hyperglycemia, or diabetes, can lead to many neurologic and systemic complications and that optimal glucose control is our goal. For our listeners, here's the question: what neurologic complication can occur from correcting hyperglycemia too quickly? What neurologic complication can occur from correcting hyperglycemia too quickly? Stick around to the end of our interview for the answer. So, Aaron, let's get right to it. You had a chance to review all the articles in this issue on the neurology of systemic disease. What do you think in all of those is the most exciting recent development for patients who fit into this category? Dr Berkowitz: Yeah, that's a great question. I think we talked about when we were putting this issue together, right, a lot of the Continuum subspecialty topics; there should have been updates on particular disease diagnostics, treatments, new phenotypes. Whereas here probably a lot less has changed in primary heart disease, primary cancer. As I'd like to say to our students trying to excite them about neurology, most specialties have new treatments, but I can name a large number of new diseases, right, that have been discovered since we've been out of training. So, a lot of the primary medicine stays the same, and the neurologic complications stay the same. But probably the thing that many readers will want to keep handy and will probably be much in need of update again in three years are the neurologic complications of all the new cancer treatments. So, if we think back to I finished training just over ten years ago when a lot of the fill-in-the-blank-umabs were coming out, CAR T therapy, and we were starting to see a lot of neurology, I remember, related to these and telling the oncologists and they said, oh, you just wait. We are seeing at the conferences that there's a lot of neurology to these. And I feel like that is always a moving target. And I think we are seeing a lot of those and it's hard to keep up with which treatments can cause which complications, which syndromes and which severities require holding the treatment when you can rechallenge longer-term complications of CAR T cell therapies now that we've learned more about the acute complications. So, Amy Pruitt from Penn has written us a fantastic article for this issue that covers a lot of the updates there. And I learned a lot from that. I feel like that's the one that just like every time the carnioplastic diseases are reviewed in Continuum, it seems like the table is another page longer from your colleagues there in Rochester teaching us about new antibodies. And I feel like, for this issue, that's one of the areas that felt like there was a lot of very new content to keep up with since last time.  Dr Jones: That's good news, right? It's good that we have new immunotherapies for cancer, but it does lead to neurologic catastrophes sometimes, and it is a moving target, really rapid. So, you mentioned that just over ten years ago you finished your training and now we see a lot more of these complex immunotherapy-related neurologic complications. What about in the other direction? Are there any things that you see less commonly now in your practice than you might have seen ten years ago right when you were finishing training?  Dr Berkowitz: I would say no, I think. I think we're seeing a lot of new stuff, and we're still seeing a high volume of the classic consults we tend to get, whether that's altered mental status in a patient who's systemically ill; weakness or difficulty reading from the ventilator in a patient who's critically ill; patient has endocarditis and has a stroke hemorrhage or mycotic aneurysm, what do we do? Yeah, one of the parts that was really fun and educational editing this issue is, I really wanted to ask the experts the questions I find that are really troubling and challenging and make sure we could understand their perspective on things like the endocarditis consult, which I always feel like each time there's some twist that even though the question is what do we do about this stroke and/or hemorrhage and/or aneurysm and is surgery safe? It seems like each time I always feel like I'm reinventing the wheel, trying to really sort out how to think about this. And we have a great article from Alvin Doss at Beth Israel and Steve Feskey from Boston Medical Center. It covers a lot of cardiology, as you know, in that article about a great section on endocarditis where every time it came back for review, I would say, but what about this? This comes up. What about this? Can you explain how you think about this for our readers? I don't know. I'd be curious to hear your perspective. It sounds like we agree on what has become more common. I don't think anything in neurology seems to become less… Dr Jones: Well, no, I guess we haven't really solved anything, I guess we haven't cured any problem. But that's okay, right? I mean, it's building on an established foundation of experience and history in our field. And you know, we mentioned earlier that in many ways this issue is kind of like a neurology consultant's handbook. We did something a little different with it in that sense. In addition to you serving as the guest editor, you have authored an article in the issue. It touches on something that we've talked about a couple of times, and I'd be interested to hear you talk through it with our listeners a little bit on how to approach the neurologic consultation. Tell us a little more about that and your article and how you approached it.  Dr Berkowitz: Oh, yeah, thanks. Well, thanks first of all for inviting me to think about a sort of introductory article to this issue. And I was trying to think about what to write about because, as you've said and we've been talking about, no one could know every neurologic complication of every medical disease, treatment, surgery, hospital context. Probably many of us don't even know all the muscle diseases, right, within neurology. So how could we know all this stuff? And we need some type of manual from our colleagues that can explain, okay, I know this patient has inflammatory bowel disease and they've had a stroke. Is that- are these related? Are these unrelated? And I thought the articles kind of answer all of these questions. What would I say beyond this patient has disease X and is on drug Y? Well, look up in this issue disease X and see what the neurology can be, common and rare and how often it's associated, how often it's the presenting feature, how often it means the treatment is failing, etc. I thought, I'm not sure there's much to say there. That's about a paragraph. And I thought, well, let's think even more broadly about neurologic consultation. And as you know, I like to think about diagnostic reasoning and clinical reasoning. And we talk a lot about framing bias right? And I think that is very common in consultative neurology because we'll be told in the consult or in the page or E-consult or whatever it is, this is a blank-year-old blank with a history of blank on treatment blank. And right away your mind is starting to say, oh, well, the patient just had heart disease, or, the patient is nine months pregnant, or, the patient is on an immune checkpoint inhibitor. And whether you want to do it or not, your mind is associating the patient's neurology with that. And it's- even if we know we're framing or anchoring, it's hard to kind of pull away from that. And most of the time, common things being common, a patient with cancer develops new neurology, It's probably the cancer, the treatment, or sometimes a paraneoplastic syndrome. But I've definitely found if you do a lot of inpatient neurology and a lot of consults that you're seeing so much and you have no choice but to apply these heuristics, because you're seeing a lot of volume quickly and the patients are in the hospital or they're being closely followed and outpatient setting by another specialist. You presume if you didn't get it quite right the first time, it's going to come back to you. And there's a little bit of difficulty figuring out, this is a case, actually, of all the altered mental status in acutely ill patients I got today, this is the one I should dig deeper in that I think this could turn out to be a stroke or encephalitis as opposed to delirium. I felt like that I really haven't approached that except knowing that it's easy to fall into traps. And so, I started to think about framing bias. You know, we talked about if we become aware of our biases, right, we're better at not falling prey to them. But it's subconscious. So, we might be applying it without even realizing, or even saying, I might be framing this case the wrong way, you can go right on framing it the wrong way. So, I want to kind of get a little more granular on what types of framing biases actually are relevant, specifically, to the console setting. And so, I tried to come up with a few more specific examples and try to think about ways that we could at least have a quick, if our knee-jerk is to associate primary disease X that the patient has or primary treatment X with neurologic symptom Y, what's at least a quick counter-knee jerk to say, what if it could be something else? So, for example, one of them I call "low signal-to-noise ratio bias." Altered mental status in the acutely ill hospitalized patient. What would you say, Lyell? 99 out of 100- 99.9 out of 100, it's not a primary neurologic disease. Is that fair to say? Dr Jones: Very high, yep. I agree. Dr Berkowitz: Yeah. But could it be a stroke? Could it be non-convulsive status epilepticus, meningitis encephalitis? So, how do we sort of counteract low signal-to-noise ratio bias, acknowledging it exists, acknowledging most of the time there is a low signal-to-noise, that it's not going to be neurology---to just for example, use the time course. This is pretty acute. Have I convinced myself this is not a stroke or a seizure or an acute neurologic infection? And if I'm not sure at the bedside, should I err on the side of more testing? Or the "curbside bias," as I call when your colleague just sends you a text message on your phone, No need to even open the chart, Dr Jones. Patient had a cerebellar stroke. Incidental. They're here for something else. Aspirin, right? Just like a super tentorial stroke. And you might reply thumbs up. And then imagine you open the CT scan and it's a huge cerebellar stroke with fourth ventricular compression- and patient can hide a lot of stroke back there, might just have a little ataxia. You were curbsided and that framed you to think, oh, they asked me, is aspirin okay for a cerebellar stroke and I said yes, without realizing actually the question should have been posed is, how do you manage a huge stroke with mass effect in the posterior fossa? So, these types of biases, I come up with five of them, I won't go through all of them. I'm in the article to sort of acknowledge for the reader, most of the time it's going to be what you look up in this issue, but how to think about the times where it might not be and how to be more precise about what framing is and different types of framing that occur specifically in the consultant arena. Dr Jones: And I think the longer we practice, the more of those low-frequency exceptions that you see. And, you know, and then it sticks in our mind and sometimes the bias swings the other way; people, you know, think primarily about the low frequency. And so, it's tricky. And what I really enjoyed about that article, we started talking about this probably more than a year ago, and more than a year ago, I would say relatively few clinicians were using a now widely popular large language model for clinical decision-making; we won't name the model. And now I think most clinicians are using it almost every day, right? And I think it puts a premium on how to think and how to engage with the patient, and less about the facts and the lists that a lot of conventional medical education really is derived from. So, I really appreciate that article. We can pat ourselves in the back. We had some foresight to put it in the issue, and I think it's a great addition to it. Dr Berkowitz: Thank you. Dr Jones: So, the list of potential topics when we think about the neurologic manifestations of systemic disease, we tend to break it down by organ systems, right? But the amount of things that could end up in the issue is almost infinite. Is there anything that, when you were putting this issue together---either in terms of the topics or editing the articles---is there anything that you wanted to include, but we just didn't have room? Dr Berkowitz: I certainly won't say we covered everything, but I will say we were able to recruit a fantastic team of authors. And as you and I also talked about at the beginning, although you could say, we're doing the movement disorders issue, let's find all the top movement disorders folks who are expert specialists in this field, there's not really a neurohematologist or a neurogastroenterologist out here. So, you and I put our heads together to think of phenomenal general neurologists in most cases, some subspecialists who know a lot about this but were also excited to read a lot more about it and assemble the existing knowledge by the practicing neurologist for the practicing neurologist. And I think with that approach and letting folks have kind of, you know, I asked some specific questions. These are topics I hope you'll cover. These are vexing questions in this area. I hope you'll find some answers to how often can this neurology be the primary feature of this rheumatologic disease with no systemic manifestations and when should we look or as we mentioned, the complicated endocarditis consult. I won't say we covered everything. This could be, and is, textbook-sized, and there are textbooks on this topic. But I think on the contrary, authors came back and had sections on things that I might not have thought to ask- to cover. Dr Sarah LaHue, my colleague here at UCSF, I asked for an article, as traditionally in this issue, on the neurology of pregnancy in the postpartum state and included, I think probably for the first time in Continuum, a fantastic review of neurologic considerations in patients in menopause, which I'm not sure has been covered before. So, things that I wouldn't have even thought to ask for. Our authors came back with some fantastic stuff. And the ICU article by Dr Shivani Ghoshal, instead of focusing just on altered mental status in the ICU, weakness in the ICU---those are all in there---I also asked her to discuss complications of procedures in the ICU. How often do procedures in the ICU cause local neuropathies or vascular injury, these types of things. Dr Jones: Yeah, me too. And I guess that's a great advertisement, that there probably are things that we didn't cover, but if there are, we can't think of them. We've done as best as we can. So now let's come back to our Continuum Audio trivia question for our listeners. And I'll repeat the question: what neurologic complication can occur from correcting hyperglycemia too quickly? And I actually think there might be two correct answers to this one. Dr Berkowitz, what do you think? Dr Berkowitz: Yeah, I was thinking of two things. I hope these are the things you're thinking of as well. One is what I think used to be referred to as insulin neuritis, sort of an acute painful small fiber neuropathy from after the initiation of insulin, I think also called treatment-induced diabetic neuropathy or something of that nature. And then the other one described, defined and classified by your colleagues there in Rochester, the diabetic lumbosacral radiculoplexis neuropathy or Bruns-Garland syndrome or a diabetic amyotropy, I think, can also---if I'm not mistaken---also occur in this context; you should have weight loss in association with diet treatment of diabetes. But how did I do? Dr Jones: Yeah, you win the prize, the first-ever prize. There's no monetary value to the prize, but pride, I think, is a good one. Yeah, those were the two I was thinking of. The treatment-induced neuropathy of diabetes is really nicely covered in Dr Rafid Mustafa's article on the neurologic complications of endocrine disorders. It's a rare condition characterized by the acute/subacute onset of diffuse neuropathic pain and some usually some autonomic dysfunction. And it occurs when you have rapid and substantial reductions in blood glucose levels. And you can almost map it out. There was a study from 2015 which is referenced in the article, which found that a drop in hemoglobin A1c of 2 to 3% over three months confers about a 20% absolute risk of developing this treatment-induced neuropathy of diabetes, and a drop of more than 4%, more than 80% risk. So, very substantial. And then in the other---we see this commonly in patients with diabetic lumbosacral radiculoplexis neuropathy---they have the subacute onset of usually asymmetric pain and weakness in the lower limbs that tends to occur more frequently in patients who have had recent better control of their sugar. We can also see it in the upper limbs too. So, you get a perfect score. Dr Berkowitz, well done. Again, I want to thank you. I want to thank you for such a great issue, a great article to kick off the issue, and a great discussion of the neurology of systemic disease. Today I learned a lot talking today, I learned a lot reading the issue. Really grateful for your leadership of putting it together, pulling together a really great author panel, and I think it will come in handy not just for our junior readers and listeners, but also our more experienced subscribers as well. Dr Berkowitz: Thank you so much. Like I said, it was a big honor to be invited to guest edit this issue. I've read it every three years since I started residency. It's always one of my favorite issues. As you said, a manual for consultative neurology, and I learned a ton from our authors and really appreciate the opportunity to work with you and the amazing Continuum team to bring this from an idea, as you said, probably over a year ago to a printed issue. So, thanks again, Lyell. Dr Jones: Thank you. And again, we've been speaking with Dr Aaron Berkowitz, guest editor of Continuum's most recent issue on the neurology of systemic disease. Please check it out, and thank you to our listeners for joining today. Dr Monteith: This is Dr Teshamae Monteith, Associate Editor of Continuum Audio. If you've enjoyed this episode, you'll love the journal, which is full of in-depth and clinically relevant information important for neurology practitioners. Use the link in the episode notes to learn more and subscribe. Thank you for listening to Continuum Audio.

Unlock the Future of Brand Growth Discover what's changing fastest in how brands grow today, straight from industry leaders who are shaping modern commerce. The RETHINK Retail Podcast takes you behind the scenes of marketplace strategies, ecosystem-driven growth, and omnichannel success. Learn from the expertise of Tim Derner of Authentic Brands Group and Remington Tonar of Cart.com as they explore: - Marketplace acceleration: How Amazon, TikTok Shop, and global platforms are driving brand expansion. - Ecosystem advantage: Why combining brands, IP, talent, entertainment, and retail partnerships creates outsized impact. - Omnichannel pitfalls: The most common traps brands fall into when trying to be everywhere at once. - AI in operations: Where automation and intelligence are quietly improving efficiency without being the headline. Whether you're a brand manager, retailer, or commerce innovator, this episode provides actionable insights to help your brand scale globally, simplify operations, and stay ahead of the competition.

This month Alt.Latino's been looking at the music of Venezuela from a lot of different angles. For this episode, we've invited trumpet player and producer Ella Bric to be our guest DJ. She shared what she thinks are the most socially, culturally and politically impactful pieces of music to come out of Venezuela in the last half century.Ella Bric grew up in a migrant-rich town in Venezuela called San Antonio de los Altos, surrounded by a culturally-minded, socially conscious community. She's now based in New York, and in recent years has positioned herself as a prolific producer on the rise in the Latin music space. In 2018, she won a Latin Grammy for Producer of the Year, and she says her art comes from a curiosity about the state of the world and her desire to reflect that.(00:00) Introduction(01:46) La Vida Bohème, 'Hornos del Cal'(06:41) Betsayda Machado & Parranda el Clavo, 'Sentimiento'(11:35) María Rodríguez, 'Los Dos Titanes'(15:11) Ali Primera, 'Techos de Cartón'(19:52) Linda Briceño & Orlando Watson, 'Unfinished Song'(24:38) Desorden Público, 'Politicos Paraliticos'(27:36) Bucle Lunar, 'Subió El Maldito Dolar'This podcast episode was produced by Noah Caldwell. The executive producer of NPR Music is Suraya Mohamed.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

This month we've been looking at the music of Venezuela from a lot of different angles. For this episode, we've invited trumpet player and producer Ella Bric to be our guest DJ. She shared what she thinks are the most socially, culturally and politically impactful pieces of music to come out of Venezuela in the last half century.Ella Bric grew up in a migrant-rich town in Venezuela called San Antonio de los Altos, surrounded by a culturally-minded, socially conscious community. She's now based in New York, and in recent years has positioned herself as a prolific producer on the rise in the Latin music space. In 2018, she won a Latin Grammy for Producer of the Year, and she says her art comes from a curiosity about the state of the world and her desire to reflect that.(00:00) Introduction(01:46) La Vida Bohème, 'Hornos del Cal'(06:41) Betsayda Machado & Parranda el Clavo, 'Sentimiento'(11:35) María Rodríguez, 'Los Dos Titanes'(15:11) Ali Primera, 'Techos de Cartón'(19:52) Linda Briceño & Orlando Watson, 'Unfinished Song'(24:38) Desorden Público, 'Politicos Paraliticos'(27:36) Bucle Lunar, 'Subió El Maldito Dolar'This podcast episode was produced by Noah Caldwell. The executive producer of NPR Music is Suraya Mohamed.Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

This month, the gals invite Brandon Schexnayder from Southern Gothic on to chitchat about ghost gaslighting, sexy sheep, party raccoons, a porta-potty problem, and a brand-new fear for Amanda. Tune in for January's episode of Gossip at the Corpse Cart! For a full list of show sponsors, visit https://wineandcrimepodcast.com/sponsors. To advertise on Wine & Crime, please email ad-sales@libsyn.com or go to advertising.libsyn.com/winecrime.